PETRI DISH PERSPECTIVES

Manead Khin
  • 0.0 (0)
  • LIFE SCIENCES

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 6D AGO

    Episode 34: Astellas

    Send us a text In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global collaboration. We unpack how Astellas quietly repositioned itself toward oncology, gene therapy, and regenerative medicine while navigating the challenges of globalization, risk-taking, and long development timelines. This episode is about how long-term thinking, scientific rigor, and cultural continuity can still win in an industry driven by speed. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Astellas #Biotech #Pharma #DrugDiscovery #Oncology #PrecisionMedicine #JapanesePharma #Xtandi #TransplantMedicine #Biopharma #LifeSciences #PharmaStrategy #PetriDishPerspectives Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    26 min

  2. DEC 11

    Episode 33: Novartis

    Send us a text In this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention. We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’ll learn how visionary leaders, bold pipeline bets, and a focus on precision medicine shaped Novartis into a global powerhouse. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Novartis #BiotechPodcast #DrugDiscovery #Gleevec #CAR_T #GeneTherapy #OncologyInnovation #PharmaStrategy #PetriDishPerspectives #HealthcareInnovation #PrecisionMedicine #LifeSciences #BiotechResearch Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    24 min

  3. DEC 4

    Episode 32: Recursion

    Send us a text Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation. In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS, a closed-loop platform that generates massive, proprietary biological data. Learn about the company's bold vision, from the crucial $50 million NVIDIA investment and the strategic merger with Exscientia to the immense computational power of the Boltz-2 supercomputer. We analyze their pipeline progress in oncology and rare diseases, discuss the challenges of high cash burn (like the recent pipeline streamlining in November 2025), and examine their critical partnerships with giants like Roche/Genentech. Discover why Recursion is leading the charge to build the digital "Map of Biology and Chemistry" to cut drug discovery time from a decade to mere years. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Recursion #TechBio #AIDrugDiscovery #NVIDIA #Biotech #PharmaInnovation #MachineLearning #OmicsData #Genomics #RecursionOS #PetriDishPerspectives #BiotechPodcast Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    23 min

  4. DEC 1

    November 2025: Biotech & Pharma NEWS Roundup

    Send us a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025! This month was dominated by a surge in M&A activity, with high-profile bidding wars!  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    11 min

  5. NOV 27

    Episode 31: Bispecific Antibodies

    Send us a text Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell. In this episode, we trace the incredible scientific journey of BsAbs: from the manufacturing failure of the Quadroma Problem to the engineering solution of the "Knobs-into-Holes" strategy and the super-potent BiTE format. You'll hear how drugs like Blinatumomab have become "off-the-shelf" T-cell therapies, transforming treatment for blood cancers. We also explore the challenges of managing side effects like Cytokine Release Syndrome (CRS) and the promise of using BsAbs to conquer solid tumors. If you want to understand the sharp edge of modern cancer research, this is a must-listen. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #BispecificAntibodies #Immunotherapy #CancerResearch #BiotechBreakthrough #Oncology #TCellEngager #SciencePodcast #DrugDiscovery #PetriDishPerspectives Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    23 min

  6. NOV 20

    Episode 30: Metsera

    Send us a text In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company. If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciences Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    25 min

  7. NOV 13

    Episode 29: Charles River Laboratories

    Send us a text In this episode of Petri Dish Perspectives, we dive into the untold story of Charles River Laboratories, the quiet giant behind nearly every major drug you’ve ever heard of. From its origins on the banks of Massachusetts’ Charles River, where Dr. Henry Foster began breeding lab rats to support post-war research, to its evolution into a global scientific infrastructure company, Charles River has shaped the very foundation of modern drug development. We’ll explore how a small animal breeding business became the unseen force driving pharmaceutical innovation, the company’s expansion under James Foster, and its deep involvement in gene therapy, biologics, and vaccine testing. You’ll also hear about the complex ethical landscape Charles River navigates balancing innovation and regulation in a world demanding both faster cures and higher transparency. By the end of this episode, you’ll understand why behind every breakthrough, from oncology to rare diseases, there’s often a quiet partner ensuring that science moves safely from lab bench to bedside. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    24 min

  8. NOV 6

    Episode 28: Regeneron

    Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the remarkable story of Regeneron Pharmaceuticals, from its humble beginnings in Tarrytown to becoming one of the world’s leading biotech innovators. Discover how founders Leonard Schleifer and George Yancopoulos turned early failure into scientific triumph with breakthrough drugs like Eylea, Dupixent, and the COVID-19 antibody cocktail that changed the global response. We explore how Regeneron built a culture rooted in pure science, balanced innovation with controversy, and redefined what it means to be a biotech powerhouse in a pharma-dominated world. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechUnleashed #Regeneron #LeonardSchleifer #GeorgeYancopoulos #Eylea #Dupixent #VelocImmune #BiotechPodcast #LifeSciences #PharmaInnovation #DrugDiscovery #COVID19 #HealthcareInnovation #BiotechStorytelling Support the show © 2025 Petri Dish Perspectives LLC. All rights reserved.

    23 min
See All (35)

About

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Information

  • Creator
    Manead Khin
  • Years Active
    2K
  • Episodes
    35
  • Rating
    Clean
  • Copyright
    © 2025 PETRI DISH PERSPECTIVES
  • Show Website
    PETRI DISH PERSPECTIVES

You Might Also Like